نتایج جستجو برای: her2 antigen

تعداد نتایج: 214094  

Journal: :Journal for ImmunoTherapy of Cancer 2021

Background Solid tumors display pronounced antigen heterogeneity and clinical studies have shown that escape from therapy occurs rapidly, limiting the persistence efficacy of CAR T cells. Here we present dual triple-antigen binding proteins bridge cells to multiple antigens, allowing a simultaneous attack on tumor antigens by single antibody domain. We call these Engager proteins. can be encode...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Shigehisa Kitano Shinichi Kageyama Yasuhiro Nagata Yoshihiro Miyahara Atsunori Hiasa Hiroaki Naota Satoshi Okumura Hiroshi Imai Taizo Shiraishi Masahiro Masuya Masakatsu Nishikawa Junzo Sunamoto Kazunari Akiyoshi Takashi Kanematsu Andrew M Scott Roger Murphy Eric W Hoffman Lloyd J Old Hiroshi Shiku

PURPOSE We developed a complex of tumor antigen protein with a novel nanoparticle antigen delivery system of cholesteryl pullulan (CHP). To target HER2 antigen, we prepared truncated HER2 protein 1-146 (146HER2) complexed with CHP, the CHP-HER2 vaccine. We designed a clinical study to assess the safety of the vaccine and HER2-specific T-cell immune responses measured by the newly developed enzy...

2014
Tiara Byrd Kristen Fousek Antonella Pignata Amanda Wakefield Zakaria Grada Kevin Aviles-Padilla Bradley S Fletcher Meenakshi Hegde Brad St Croix Nabil Ahmed

Background We have previously demonstrated the efficacy of HER2 specific chimeric antigen receptor (CAR) T cells in animal models of human cancer. While HER2 CAR T cells induced tumor regression, tumors recurred in a subset of animals. Lytic co-targeting of the tumor endothelium could represent a strategy that enhances tumor control. Tumor endothelium marker 8 (TEM8) is a recently described tum...

Journal: :Onkologie 2005
Hans-Joachim Stemmler Petra Stieber Dorit Lässig Volker Heinemann

BACKGROUND HER2 is overexpressed in 20-30% of breast cancers. Compared to chemotherapy alone, chemotherapy with trastuzumab improves clinical outcome in patients with HER2-positive metastatic breast cancer (MBC). In general, HER2 status in a primary lesion predicts the status of metastases, so that biopsy of metastatic lesions appears unnecessary. CASE REPORT A 39-year old woman was diagnosed...

Journal: :Clinical breast cancer 2001
K L Knutson M L Disis

The identification and characterization of tumor antigens has facilitated the development of immune-based cancer prophylaxis and therapy. Cancer vaccines, like viral vaccines, may be effective in cancer prevention. Adoptive T-cell therapy, in contrast, may be more efficacious for the eradication of existing malignancies. Our group is examining the feasibility of antigen-specific adoptive T-cell...

Journal: :Biomedical Journal of Scientific and Technical Research 2023

Bispecific antibodies (BsAbs) have been developed, with one antigen-binding site coordinated against the CD3 receptor (which activates cytotoxic T lymphocytes) and other specific antigens found on cancer cells (CD19, CD20, CD33, CD123, HER2, epithelial cell adhesion molecule [EpCAM], BCMA, CEA, others) [1].

Journal: :American journal of clinical pathology 2010
Anthony Rhodes Julia Sarson Emma E Assam Sarah J R Dean Edward C Cribb Andrew Parker

The reliability of the rabbit monoclonal antibodies SP1, SP2, SP3, and 4B5 was immunohistochemically assessed on a range of 96 invasive breast carcinomas and the results compared with those achieved with established antibody markers for estrogen receptors (6F11), progesterone receptors (PgR636), and HER2 (polyclonal A0485 and clone CB11), with HER2 status validated by fluorescence in situ hybri...

Journal: :Molecular therapy. Methods & clinical development 2021

The quality of chimeric antigen receptor (CAR)-T cell products, including the expression memory and exhaustion markers, has been shown to influence their long-term functionality. manufacturing process CAR-T cells should be optimized prevent early T during expansion. Activation by monoclonal antibodies is a critical step for expansion, which may sometimes induce excess stimulation cells. Given t...

Journal: :Advances in experimental medicine and biology 1998
D D Schoof J W Smith M L Disis P Brant-Zawadski W Wood T Doran E Johnson W J Urba

Tumor-assocla,ted antigens have been identified on a variety of human neoplasms. Each of these antigens may be able to serve as a target for an immune respOf.lse, the result of which would be eliminatjon of the tumor celL An essential component of this immune response is the presentation of antigen to potential effector cells. This can be accom­ plished via host professional antigen~presenting ...

Journal: :International journal of clinical and experimental medicine 2015
Qun Wang Wei Cao Zhi-Gang Yang Guang-Fa Zhao

BACKGROUND Anti-CD11c antibodies target to the CD11c receptor that mediates antigen presentation to T cells by dendritic cells (DCs). To exploit these properties for immunization purposes, we obtained DC-targeting DNA vaccines by fusing tumor-associated antigen HER2/neu ectodomain to single chain antibody fragment (scFv) from N418 (scFv(N418)), a monoclonal antibody binding the mouse DC-restric...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید